A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

BACKGROUND: EDP‐305 is a novel and potent farnesoid X receptor (FXR) agonist, with no/minimal cross‐reactivity to TGR5 or other nuclear receptors. Herein we report therapeutic efficacy of EDP‐305, in direct comparison with the first‐in‐class FXR agonist obeticholic acid (OCA), in mouse models of liv...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ping, Wei, Guangyan, Huang, Pinzhu, Li, Wenda, Qi, Xiaolong, Lin, Yi, Vaid, Kahini A., Wang, Jun, Zhang, Shucha, Li, Yang, Or, Yat Sun, Jiang, Li‐Juan, Popov, Yury V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Gut‐liver Axis, Immunology, Immune Mediated and Cholestatic Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384094/
https://www.ncbi.nlm.nih.gov/pubmed/32329946
http://dx.doi.org/10.1111/liv.14490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384094/
https://www.ncbi.nlm.nih.gov/pubmed/32329946
http://dx.doi.org/10.1111/liv.14490

Ejemplares similares